Tak­ing on lousy side ef­fects of ex­ist­ing meds, NEA-backed Xoc tack­les Parkin­son’s/mi­graines with $30M Se­ries A

New En­ter­prise As­so­ciates is back­ing a start­up near San Jose that’s us­ing old clin­i­cal da­ta — paired with new tech — to come up with nov­el drugs for Parkin­son’s dis­ease and mi­graines. By mim­ic­k­ing the things that work in old drugs while aban­don­ing side-ef­fect-caus­ing trig­gers, the hope is to de­sign drugs that lack the grim re­ac­tions of those al­ready on the mar­ket.

The com­pa­ny, called Xoc (pro­nounced “shock”) Phar­ma­ceu­ti­cals, raised $30 mil­lion in this new Se­ries A round led by NEA (one of the world’s largest ven­ture firms, with $18 bil­lion in as­sets un­der man­age­ment).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.